NDRA · ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. faces imminent risk of delisting from Nasdaq following the Staff's April 20, 2026 letter, which cited stockholders’ equity of $2,260,120 in the Form 10-K for the year ended December 31, 2025, below the $2,500,000 minimum required by Nasdaq Listing Rule 5550(b)(1). This follows a prior deficiency notice on May 27, 2025, a compliance plan submission on July 11, 2025, an extension to November 24, 2025, and temporary compliance determination on November 18, 2025 based on a prior 8-K. The renewed non-compliance underscores ongoing financial challenges, as periodic reports must now demonstrate sustained equity levels under monitoring. The Company's request for a hearing before the Nasdaq Hearings Panel will pause delisting actions until a decision and any potential extension are issued. Management is evaluating options to resolve the deficiency but provides no guarantees of success, highlighting material uncertainty for investors regarding continued Nasdaq listing and access to capital markets.